<SEC-DOCUMENT>0001193125-17-040114.txt : 20170213
<SEC-HEADER>0001193125-17-040114.hdr.sgml : 20170213
<ACCEPTANCE-DATETIME>20170213141502
ACCESSION NUMBER:		0001193125-17-040114
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170213
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170213
DATE AS OF CHANGE:		20170213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		17598086

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d301019d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;13, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267) 440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;8.01.</U></TD>
<TD ALIGN="left" VALIGN="top"><U>Other Events</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2017, we announced that we had entered into a
License and Collaboration Agreement (the &#147;Agreement&#148;) with ApolloBio Corp. (&#147;ApolloBio&#148;). While the Agreement has been executed by the parties, the Agreement by its terms will become effective on the date that the ApolloBio board
of directors and stockholders approve the Agreement, which is anticipated to occur in the next few weeks, at which time we will file another Form 8-K to report the Agreement as of the effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the collaboration and license agreement, we will receive $15 million in upfront and near term payments comprised of an initial $3
million signing fee and a $12 million milestone upon lifting of the VGX-3100 phase 3 pre-initiation clinical hold by the FDA. Under a separate stock purchase agreement, ApolloBio will invest in our common stock subsequent to lifting of the clinical
hold at a volume weighted average price encompassing a trading period prior to and following the lifting of the clinical hold. The stock purchase agreement will become effective at the same time the Agreement becomes effective, at which time we will
file another Form 8-K to report the stock purchase agreement as of the effective date. The aggregate investment under the stock purchase agreement, which is expected to be completed in the first half of 2017, will not exceed $35 million and may be a
lower amount such that ApolloBio will not be our largest shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ApolloBio will fund all clinical development costs within the
licensed territory, and will pay us up to $20 million based upon the achievement of certain regulatory milestones in the United States, China and Korea, and double digit royalties on net sales of VGX-3100. The agreements are subject to People&#146;s
Republic of China (PRC) corporate and regulatory approvals, and payments are subject to PRC currency approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13,
2017, we issued a press release, which file as Exhibit 99.1 to, and incorporate by reference in, this Form 8-K current report as though fully set forth herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01.</U></TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February 13, 2017</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;13, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d301019dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g301019g0213200305260.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>NEWS RELEASE</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CONTACTS:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bernie Hertel, Inovio Pharmaceuticals, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-410-3101,</FONT></FONT> <U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jeff Richardson, Inovio Pharmaceuticals, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio and ApolloBio to Collaborate on Development and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commercialization of HPV <FONT STYLE="white-space:nowrap">Pre-cancer</FONT> Immunotherapy <FONT STYLE="white-space:nowrap">VGX-3100</FONT>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in Greater China </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio to receive up to $50&nbsp;million in upfront and near term </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>payments and equity investment </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH
MEETING, Pa. &#150; February&nbsp;13, 2017 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ: 430187) with the exclusive right to
develop and commercialize <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> Inovio&#146;s DNA immunotherapy product designed to treat <FONT STYLE="white-space:nowrap">pre-cancers</FONT> caused by human papillomavirus (HPV), within Greater China
(China, Hong Kong, Macao, Taiwan). The agreement provides for potential inclusion of the Republic of Korea three years following the effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration and license agreement, Inovio will receive $15&nbsp;million in upfront and near term payments comprising an initial $3&nbsp;million
signing fee and a $12&nbsp;million milestone upon lifting of the <FONT STYLE="white-space:nowrap">VGX-3100</FONT> phase 3 <FONT STYLE="white-space:nowrap">pre-initiation</FONT> clinical hold by the FDA. Under a separate equity agreement, ApolloBio
will invest in Inovio common stock subsequent to lifting of the clinical hold at a volume weighted average price encompassing a trading period prior to and following the lifting of the clinical hold. The aggregate investment, which is expected to be
completed in the first half of 2017, will not exceed $35&nbsp;million and may be a lower amount such that ApolloBio will not be the largest shareholder in Inovio. ApolloBio will fund all clinical development costs within the licensed territory, and
will pay Inovio up to $20&nbsp;million based upon the achievement of certain regulatory milestones in the US, China and Korea, and double digit royalties on net sales of <FONT STYLE="white-space:nowrap">VGX-3100.</FONT> The agreements are subject to
People&#146;s Republic of China (PRC) corporate and regulatory approvals, and payments are subject to PRC currency approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This collaboration on <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> encompasses the treatment and/or prevention of <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> HPV infections and <FONT STYLE="white-space:nowrap">HPV-driven</FONT> dysplasias, and excludes <FONT
STYLE="white-space:nowrap">HPV-driven</FONT> cancers and all combinations of VGX-3100 with other immunostimulants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s
President and Chief Executive Officer, said, &#147;As Inovio continues to focus on the path to regulatory approvals and commercialization strategies in the U.S. and European countries, this agreement opens up Greater China for our lead program and
first phase III product. We believe that ApolloBio is a strong partner that brings significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the healthcare market in China.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weiping Yang, Chief Executive Officer of ApolloBio Corporation, said, &#147;We are delighted to begin
2017 with a strategic collaboration with Inovio. <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is the world&#146;s first therapeutic vaccine being developed for HPV <FONT STYLE="white-space:nowrap">pre-cancers.</FONT> This collaboration, license
and equity investment marks our determination to introduce late stage innovative new drugs to meet severely unmet medical needs within the Greater China region.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">VGX-3100</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">VGX-3100</FONT> is an <FONT STYLE="white-space:nowrap">HPV-specific</FONT> immunotherapy that is being developed as a <FONT STYLE="white-space:nowrap">non-surgical</FONT> treatment for high-grade cervical dysplasia and
related underlying persistent HPV infection. <FONT STYLE="white-space:nowrap">VGX-3100</FONT> works in vivo to activate functional, antigen-specific, <FONT STYLE="white-space:nowrap">CD-8</FONT> <FONT STYLE="white-space:nowrap">T-cells</FONT> to
clear persistent HPV 16/18 infection and cause regression of <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> cervical dysplasia. In a phase II trial, <FONT STYLE="white-space:nowrap">VGX-3100</FONT> demonstrated clinical efficacy and was
generally well tolerated, without the side effects and obstetric risks associated with surgical excision. <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">HPV-specific</FONT> immunotherapy that targets the underlying cause of cervical dysplasia, providing an opportunity for
women to reduce their risk of cervical cancer without undergoing an invasive surgical procedure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About HPV and Cervical Dysplasia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which kills more than 250,000 women every year worldwide. Among
the 300&nbsp;million women currently infected with HPV, 500,000 will be diagnosed with cervical cancer each year. Two types of HPV (HPV 16 and HPV 18) cause 70% of cervical cancer cases. High-grade cervical dysplasia is also caused by persistent HPV
infection and is a <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> condition that can progress to cervical cancer if left untreated. Globally the number of high-grade cervical dysplasia cases is estimated to be in the range of 10&nbsp;million.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently there are no approved medical treatments for persistent HPV infection or cervical dysplasia. The primary treatment for high-grade cervical
dysplasia is surgical excision of the <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> lesion and a margin of healthy cervical tissue. Because surgical excision does not treat the underlying HPV infection that causes cervical dysplasia, there
is a <FONT STYLE="white-space:nowrap">10-16%</FONT> risk of disease recurrence. Women with persistent HPV infection after surgical excision remain at high risk for cervical cancer. In addition, surgical treatment is associated with pain and
cramping, and a risk for post-surgical bleeding, infection, and <FONT STYLE="white-space:nowrap">pre-term</FONT> delivery and miscarriages during future pregnancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ApolloBio Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ApolloBio Corporation (NEEQ:
430187) is a leading Chinese biomedical company committed to research and development of innovative new medicines, accessing such new medicines through <FONT STYLE="white-space:nowrap">in-licensing,</FONT> and additionally providing medical
services. ApolloBio Corp. is focused on pharmaceutical products with significant market potential in China in the three major fields of oncology, liver disease, and cardio-cerebrovascular disease; providing efficient access for American biomedical
companies to enter into the Chinese market; and aiming to bring the newest and best medicines across the globe to the Chinese people. For more information, visit www.apollobio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking
immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates
with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The
Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more
information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # # </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including the
agreements with ApolloBio, our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a number of factors, including the timing of the lifting of the <FONT STYLE="white-space:nowrap">VGX-3100</FONT> phase 3 <FONT STYLE="white-space:nowrap">pre-initiation</FONT> clinical
hold, receipt of by ApolloBio of corporate and PRC regulatory approvals, uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, including <FONT
STYLE="white-space:nowrap">VGX-3100,</FONT> the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our
ability to support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we
license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the
company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents
and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s
technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2015, our Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended&nbsp;September 30, 2016,&nbsp;and other regulatory filings from time to time. There can be no assurance that the approvals required
under the ApolloBio agreements will be obtained, that <FONT STYLE="white-space:nowrap">VGX-3100</FONT> or any other product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies for <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> will be supportive of regulatory approvals required to market licensed products, including in Greater China, or that any of the forward-looking information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g301019g0213200305260.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g301019g0213200305260.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 04# 2(  A$! Q$!_\0
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MRG(J6N/^'MI=VVD3-<*R1R/F-6&/J:["@ HHHH **** "BBB@ HHHH ****
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MY_XE\4:[HFLR6RF PL-\1,?5?SKG-ST"BL7POK1US1TN)-HG0[)0O3/K6U0
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MB2#*J2Y![X&:]EH A%G;*NT6\07TV"L#7?!MAJD#/;Q+;W0&59!@$^XKI:*
M/%-/OKSPUK>[!5XGV2Q_WAWKV:VN([NUBN(CE)%#*?8UYE\0[5(==CF4 &:(
M%OJ.*ZWP)<-/X7@#'/ELR#Z T =+1110 5Y=\1O^0_#_ -<!_,UZC7EWQ&_Y
M#\/_ %P'\S0!UW@;_D5K?_>;^=;\_P#Q[R?[A_E6!X&_Y%:W_P!YOYUOS_\
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H[CT-:5S:6]Y%Y5S!'*F<[77(I\44<$2QQ(J1J,!5& * 'T444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
